Advanced Search

Study Preview



Study Title and Description

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.



Key Questions Addressed
3 Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Author Jolly EE., Bjarnason NH., Neven P., Plouffe L., Johnston CC., Watts SD., Arnaud CD., Mason TM., Crans G., Akers R., Draper MW.
Country Department of Obstetrics and Gynecology, Ottawa General Hospital, Ottawa, Canada.
Year -- Not Found --
Numbers Pubmed ID: 12851517

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-4


Results & Comparisons

No Results found.